Chantal Richer
Papers
1
Total Citations
76
H-Index
1
About
Dr. Chantal Richer is a distinguished molecular geneticist whose pioneering work has significantly advanced the field of pharmacogenomics, particularly in the rapid detection of genetic variants affecting drug metabolism. Her most-cited research, the 1999 study on "Rapid Detection of CYP1A1, CYP2D6, and NAT Variants by Multiplex Polymerase Chain Reaction and Allele-Specific Oligonucleotide Assay," has garnered 76 citations, underscoring its lasting impact on personalized medicine. This seminal contribution introduced a high-throughput method for simultaneously identifying polymorphisms in key cytochrome P450 and N-acetyltransferase genes, enabling more efficient screening for individual differences in drug response and toxicity risk. Dr. Richer’s work has been instrumental in translating genetic insights into clinical applications, facilitating safer and more effective therapeutic strategies. Her innovative approach to multiplex PCR and allele-specific assays has become a cornerstone in genetic testing laboratories, influencing subsequent research in cancer pharmacogenetics and drug safety. Through this foundational study, Dr. Richer has helped shape the modern landscape of precision medicine, empowering clinicians to tailor treatments based on a patient’s genetic profile.
Research Focus
Key Achievements
Top Papers
- 1